Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anixa Diagnostics
San Jose, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Anixa Biosciences has two lead clinical programs in Phase 1: a preventative vaccine for triple-negative breast cancer (TNBC) in collaboration with Cleveland Clinic, and a CAR-T cell therapy for ovarian cancer in partnership with Moffitt Cancer Center. Early data from these trials show encouraging immune responses and safety outcomes, though both are in early stages and efficacy readouts are pending.
- Therapeutic areas
- Oncology
- Modalities
- VaccineCAR-T cell therapyCell therapyImmunotherapy
- Industry
- Biotech
02
Partnerships
Cleveland ClinicMoffitt Cancer Center
Beyond the preview
Go deeper on Anixa Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anixa Diagnostics.